Filip Janku, M.D., Ph.D., is a distinguished medical professional who currently holds the position of Chief Medical Officer at MONTE ROSA THERAPEUTICS INC. Dr. Janku's career is marked by significant contributions to the field of oncology, particularly in the development and application of targeted therapies. He earned his M.D. and Ph.D. from Charles University in Prague, Czech Republic, and has since built an impressive resume in both clinical practice and research. His expertise spans various aspects of cancer treatment, including molecular profiling and precision medicine, which he has utilized to advance patient care and outcomes. Before joining MONTE ROSA THERAPEUTICS INC., Dr. Janku held notable positions at prestigious institutions such as the MD Anderson Cancer Center, where he served as an Associate Professor in the Department of Investigational Cancer Therapeutics. During his tenure, he led numerous clinical trials and contributed to groundbreaking research in the field of oncology. His work has been published in several high-impact journals, reflecting his commitment to advancing the scientific understanding of cancer and its treatment. Dr. Janku's transition to MONTE ROSA THERAPEUTICS INC. as Chief Medical Officer signifies a pivotal step in his career, allowing him to steer the company's clinical development strategy and oversee the advancement of its innovative therapeutic pipeline. At MONTE ROSA THERAPEUTICS INC., Dr. Janku plays a crucial role in guiding the company's mission to develop novel molecular glue degrader (MGD) therapies. His leadership is instrumental in translating the company's cutting-edge research into viable treatment options for patients with serious diseases. With his deep understanding of oncology and extensive experience in clinical development, Dr. Janku is well-positioned to drive the company's efforts in bringing transformative therapies to market. His dedication to improving patient outcomes and his strategic vision for the company's future make him an invaluable asset to MONTE ROSA THERAPEUTICS INC.